Abstract 450P
Background
Patients with malignant tumours may suffer from nausea as a side-effect of chemo-/radiotherapy. Antiemetic drugs can cause dizziness, which may lead to falls and decrease quality of life. Complementing research on painkiller-associated dizziness [1], we now focus on dizziness in association with antiemetic drugs.
Methods
A systematic review is provided on dizziness in association with antiemetic drugs. A PubMed literature search was carried out for all articles in core clinical journals until 30 June 2019.
Results
A total of 411 articles were identified. No study evaluated dizziness caused by antiemetic drugs as a primary endpoint. A focus on dizziness as a secondary endpoint revealed four studies with class 1a (meta-analysis) or 1b (randomized controlled trial) level of evidence (LoE). In cisplatin-based chemotherapy, there is LoE 1b that the 5-hydroxytryptamine 3 receptor antagonists (5-HT(3)RA) ondansetron [2] or the combination of tropisetron and dexamethasone [3] are better in terms of antiemetic potential and dizziness than metoclopramide [2] or metoclopramide plus dexamethasone plus diphenhydramine [3]. Among 5-HT(3)RAs, a meta-analysis with over 6000 patients [4] revealed that palonosetron had the lowest incidence of nausea and dizziness (LoE 1a). The neurokinin-1 receptor rolapitant was associated with less nausea than ondansetron plus dexamethasone in a randomized controlled trial (LoE 1b) including 454 patients and had a descriptively but not significantly higher incidence of dizziness [5].
Conclusions
5-HT(3)RAs, particularly palonosetron, have an advantage with regard to antiemetic efficacy and frequency of reported dizziness when compared to metoclopramide [2-4]. The neurokinin-1 receptor rolapitant is a possible alternative [5]. References: 1. Spiegel R, et al. Ann Oncol. 2018 Oct;29(suppl_8):1793P. doi: 10.1093/annonc/mdy300.107 2. Tsavaris N, et al. Acta Oncol. 1995;34(2):243-6. doi: 10.3109/02841869509093962 3. Chua DT, et al. Br J Clin Pharmacol. 1996 May;41(5):403-8. doi: 10.1046/j.1365-2125.1996.03268.x 4. Popovic M, et al. Support Care Cancer. 2014 Jun;22(6):1685-97. doi: 10.1007/s00520-014-2175-6 5. Rapoport B, et al. Support Care Cancer. 2015 Nov;23(11):3281-8. doi: 10.1007/s00520-015-2738-1.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The first author and the last author.
Funding
Has not received any funding.
Disclosure
S.I. Rothschild: Honoraria (institution), Honoraria for advisory boards to the institution: AbbVie; Honoraria (institution), Honoraria for advisory boards to the institution: AstraZeneca; Honoraria (institution), Honoraria for advisory boards to the institution: Boehringer Ingelheim; Honoraria (institution), Honoraria for advisory boards to the institution: BMS; Honoraria (institution), Honoraria for advisory boards to the institution: Eisai; Honoraria (institution), Honoraria for advisory boards to the institution: Eli Lilly; Honoraria (institution), Honoraria for advisory boards to the institution: Merck; Honoraria (institution), Honoraria for advisory boards to the institution: MSD; Honoraria (institution), Honoraria for advisory boards to the institution: Novartis; Honoraria (institution), Honoraria for advisory boards to the institution: Pfizer; Honoraria (institution), Honoraria for advisory boards to the institution: Roche; Honoraria (institution), Honoraria for advisory boards to the institution: Takeda; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Boehringer Ingelheim; Research grant / Funding (self): BMS; Research grant / Funding (self): Eisai. R. Kalla: Research grant / Funding (self), Grant #320030_173081: National Science Foundation of Switzerland. All other authors have declared no conflicts of interest.
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract